# Developing a P4 Medicine Approach to Obstructive Sleep Apnea

> **NIH NIH P01** · UNIVERSITY OF PENNSYLVANIA · 2024 · $2,292,560

## Abstract

ABSTRACT
 This program is directed at developing a new approach to OSA care based on the principles of Precision
Medicine, with a focus on improving prediction, prevention and personalization. The program has 4 projects and
3 cores to support the work of the investigators. Project 01 (Genetics of Extreme Phenotypes of OSA and
Associated Upper Airway Anatomy) is focused on identifying both common and rare genetic variants that are
associated with risk for OSA. Since OSA has multiple pathways to disease, identifying associated genetic
variants is challenging. This project investigates gene variants associated with quantitative intermediate traits for
the disorder. The focus is on structural risk factors—both craniofacial dimensions and soft tissues. A focus is on
tongue fat, a specific heritable distribution of fat that mediates the effect of obesity in causing OSA. Machine
learning approaches have been developed to allow quantification of traits of interest from a large number of
relevant clinically-obtained CT and MR images in individuals with genetic data. Data from this project will be
used in combination with data from ongoing genetic studies to develop a polygenic risk score (PRS) for OSA
with wide-applicability. Project 02 (MicroRNAs as Biomarkers for Obstructive Sleep Apnea) will study
microRNAs as a biomarker relevant to OSA using RNA sequencing of all short microRNAs. Expression of
microRNAs is dynamic; they respond to multiple challenges, including hypoxia. MicroRNAs are being used in
development of biomarkers in multiple areas, with supportive data in OSA, albeit in relatively small samples.
Thus, we will employ a combination of a hypothesis-driven approach complimented by a broader discovery
strategy. Biomarkers will be developed to help identify cases with OSA, as well as to assess effectiveness of
therapy and to provide prognostic information about who with OSA will have blood pressure reduction with
treatment. Project 03 (Mechanisms that Account for Different Symptom Subtypes of OSA) will examine the
physiological and multi-omics determinants of robustly validated symptom subtypes of OSA. There will be an
emphasis on the excessively sleepy subtype, which has been shown to be at elevated cardiovascular risk. We
will evaluate whether there are differences in physiological responses during sleep in the different subtypes
and/or whether there are genetic, epigenetic, and metabolomic differences. Project 04 (Going from Genetic
Associations to Identification of Causative Genes) will focus on identifying causative genes that explain GWAS
associations. For genes conferring risk for OSA, we will begin with existing GWAS data complimented by data
from Project 01. For sleepiness, this project will start with recently published genetic loci, and include analyses
based on genes identified in Project 03. We will first use cell-based approaches to identify possible causative
genes. The role of these genes will be assessed in high-diversity mouse m...

## Key facts

- **NIH application ID:** 10880308
- **Project number:** 5P01HL160471-02
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Allan I Pack
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,292,560
- **Award type:** 5
- **Project period:** 2023-07-01 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10880308

## Citation

> US National Institutes of Health, RePORTER application 10880308, Developing a P4 Medicine Approach to Obstructive Sleep Apnea (5P01HL160471-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10880308. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
